Skip to Content

Join the 'Thrombocytopenia' group to help and get support from people like you.

Thrombocytopenia News

FDA Approves Mulpleta (lusutrombopag) for Thrombocytopenia in Adults with Chronic Liver Disease

Posted 31 Jul 2018 by Drugs.com

On July 31, 2018, the Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Approval was based on two randomized, double-blind, placebo-controlled trials (L-PLUS 1 and L-PLUS 2, NCT02389621) involving 312 patients with chronic liver disease and severe ...

Doptelet Approved for Liver Disease Patients Slated for a Medical Procedure

Posted 22 May 2018 by Drugs.com

MONDAY, May 21, 2018 – Doptelet (avatrombopag) has been approved by the U.S. Food and Drug Administration to treat adults with chronic liver disease who are slated to have a medical or dental procedure. People with ongoing liver disease often have low blood platelet count, which raises their risk for dangerous bleeding during a medical procedure, the agency said Monday in a news release. "This ...

FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure

Posted 22 May 2018 by Drugs.com

May 21, 2018 – The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use. “Patients with chronic liver disease who have low platelet counts and require a p ...

FDA Approves New Indication for Promacta (eltrombopag)

Posted 20 Nov 2012 by Drugs.com

LONDON, Nov. 19, 2012 – GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Promacta for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.  Promacta is the first supportive care treatment available to patients who are ineligible or poor ...

Ask a Question

Further Information

Related Condition Support Groups

Idiopathic (Immune) Thrombocytopenic Purpura, Thrombocytopenia Drug Induced, Thrombocytopenia Idiopathic, Thrombocytopenia Autoimmune, Bleeding Disorder

Related Drug Support Groups

prednisone, dexamethasone, Decadron, Doptelet, Deltasone, Sterapred DS, Mulpleta, Sterapred, avatrombopag, view more... lusutrombopag, Decadron-LA, Baycadron, Prednicen-M, Hexadrol, Prednicot, Promacta, Dexamethasone Intensol, Adrenocot LA, Dalalone, Liquid Pred, Dalalone DP, Dalalone LA, Decaject, Decaject LA, Zema Pak, eltrombopag, Orasone, Meticorten, Solurex LA, Dexasone LA, Dexacen-4, Solurex, Adrenocot, De-Sone LA, Dexacort-LA, Dexasone, Dexone, Cerezyme, Dexone LA, Primethasone, imiglucerase, Medidex, Medidex LA, Dexpak Taperpak, Dexacorten